Who’s stamping their authority in 1L NSCLC?

I can’t quite believe this is the second post in a week where we find a biotech company making a claim not fully borne out by the data.

Much depends upon what yardstick you use to make these claims and often, the devil is in the details, especially when it comes to IO trials.

In this review we explore the controversial phase 3 trial for ivonescimab in first-line non-small cell lung cancer (NSCLC) from Summit Therapeutics/Akeso Bio and whether it stands up under scrutiny.

As is often the case in these kind of situations, when every one zigs – zag!

Here we explain why things may not be all they seem…

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by